China says COVID-19 vaccine could be ready for public by November

Vaccine concept

A government official said that Serum Institute of India submitted the recommendations of the DSMB, UK and DSMB India on September 15 and requested permission to restart enrolment in the subject clinical trial.

Some volunteers have quit Johnson & Johnson's JNJ.N COVID-19 vaccine trial in Spain after news of side effects in a participant in AstraZeneca's AZN.L trial, the Spanish programme's lead investigator told Reuters on Tuesday.

Novavax, Inc. (NASDAQ: NVAX), which has a Phase 2 study underway of its coronavirus vaccine candidate NVX-CoV2373, is diligently working on partnerships to boost its manufacturing capacity.

India's top drugs regulator had in August granted permission to SII to conduct a phase II/III clinical trial of ChAdOx1 nCoV-19 coronavirus vaccine (recombinant) at various clinical trial sites in the country to determine its safety and immunogenicity.

Serum Institute of India is funding the mid and late-stage human trials for this vaccinate candidate in India.

SIIPL is expected to manufacture 1 billion doses of the vaccine candidate in 2021.

The problem in the UK?

The other two are Moderna and AstraZeneca, which announced Saturday it would resume its trial after temporarily pausing it for safety reasons. However, at the start of September, respected British medical journal The Lancet published a study prepared by the developers of Sputnik V, showing it to be 100 percent effective, producing antibodies in all 76 participants of early-stage trials.

The phase 2/3 trials of the candidate have been ongoing in the United Kingdom since the end of May. This will be crucial to ensure safety and maintain the integrity of the trials. Officials from the World Health Organisation had previously hailed AstraZeneca's vaccine candidate as one of the most promising candidates, which are now in development.

About one in seven volunteers who received a groundbreaking Russian coronavirus vaccine have complained of side effects such as muscle pain, weakness, and fever, according to the country's Minister for Health Mikhail Murashko.

CanSino, which has trials planned in Pakistan and Russian Federation for the vaccine developed with China's military research unit, did not respond to a request for comment.

When this happened late last week, Poonawala tweeted, "a$3 s I'd mentioned earlier, we should not jump to conclusions until the trials are fully concluded".